Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In patients with advanced chronic kidney disease, treatment with Prolia (denosumab) increases the risk of severe hypocalcemia, according to an updated FDA safety alert.
On January 19, 2024, the FDA announced the addition of a Boxed Warning to the labeling of denosumab (Prolia), citing evidence of an increased risk of severe hypocalcemia in patients with chronic kidney disease.
A preliminary review of side effects from popular drugs used to treat diabetes and obesity shows no link with suicidal thoughts or actions, the U.S. Food and Drug Administration said
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the...